Editorial Board
Submit Manuscript
Submit manuscript at Online Submission System or send as an e-mail attachment to the Editorial Office at manuscripts@longdom.org
Table of Contents
About the Journal
Journal of Cancer Research and Immuno-Oncology is a fast-developing open access journal in the field of cancer research. It focuses on becoming one of the best peer reviewed journal in the field of cancer research. Journal of Cancer Research and Immuno-Oncology covers a broad scope for the authors to make their valuable contributions in cancer biology, tumor, radiology, metastatis, cancer immunotherapy, oncology, radiation therapy etc
This Journal provides a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on any array of latest cancer research and Immuno-Oncology. The Journal of Cancer Research and Immuno-Oncology is a Peer Reviewed Open Access Journal supported by universally prominent Editorial Board members. Abstracts and full texts of all articles published by Journal of Cancer Research and Immuno-Oncology are freely accessible to everyone.
The journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal of Cancer Research and Immuno-Oncology or outside experts; approval of at least two independent reviewers followed by the editor is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.
submit manuscript at Online Submission System or mail us the manuscript to manuscripts@longdom.org
Fast Editorial Review Process
Journal of Cancer Research and Immuno-Oncology is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.
h-index
Articles published in Journal of Cancer Research and Immuno-Oncology have been cited by esteemed scholars and scientists all around the world. Journal of Cancer Research and Immuno-Oncology has got h-index 2 , which means every article in Journal of Cancer Research and Immuno-Oncology has got 2 average citations.
Journal Highlights
Current Issue Highlights
Short Communication
From X-Rays to Protons: Recent Advances in Cancer Radiation Therapy
Research Article
Computational Analysis of Crrna to Regulate Hsa-Mir-301b-3p and Hsa-Mir-21 Related to Metastasis and Cell Proliferation in Acute Myeloid Leukemia (AML) Using CRISPR/C2c2
Omid Moeini*, Mahsa Khatibi, Seyed Armit Hosseini, AmirAli Rahmani, Mohammadmatin Nourikhani and Arshia Aliyarzadeh